Figure 3.
In vitro toxicity of cryptophycin-55 glycinate (unconjugated drug) and compound 7 on SKRC-52 tumor cells.
. 2018 Dec 5;3(12):16743. doi: 10.1021/acsomega.8b03183
In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma
Samuele Cazzamalli
, Eduard Figueras
, Lilla Pethő
, Adina Borbély
, Christian Steinkühler
, Dario Neri
✉, Norbert Sewald
✉
Samuele Cazzamalli
Find articles by Samuele Cazzamalli
Eduard Figueras
Find articles by Eduard Figueras
Lilla Pethő
Find articles by Lilla Pethő
Adina Borbély
Find articles by Adina Borbély
Christian Steinkühler
Find articles by Christian Steinkühler
Dario Neri
Find articles by Dario Neri
Norbert Sewald
Find articles by Norbert Sewald
✉
Corresponding author.
Received 2018 Nov 14; Collection date 2018 Dec 31.
Copyright © 2018 American Chemical
Society
This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License, which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
PMCID: PMC6644080 PMID: 31458304
This corrects the article "In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin
Conjugate for the Treatment of Renal Cell Carcinomas" on page 14726.